Written by Alexander Crawford. FDA decision data sourced from RTT News.
On Tuesday the Food and Drug Administration approved Regeneron Pharmaceuticals’ (REGN) drug Eylea to treat a common cause of blindness in older patients. Some analysts predict the drug will become a blockbuster, rivaling Roche’s Lucentis, which brought in $1.4 billion in sales last year.
Eylea is a once-every-8-week injection that treats wet age-related macular degeneration, a leading cause of blindness in patients 60 and older. Roche’s Lucentis is injected twice as often at a cost of $2,000 per injection, while Eylea costs $1,850 per injection.
Capturing Market Share
40% of the market is currently held by Roche’s Lucentis, while 60% of the market is met by Roche’s Avastin. Avastin only costs $50 per injection, but it’s currently under a federal investigation after being linked to eye infections.
Regeneron estimates that 1.5 million people have wet age-related macular degeneration, with 200,000 new cases diagnosed each year. Analyst at Citigroup Inc. Yaron Werber expects the drug to hit peak sales of $1.1 billion in 2021. Werber also expects that less frequent dosing will allow Eylea to capture 16% of the US market from Lucentis.
FDA approval or rejection often has big consequences for the stocks of biotech firms putting their drugs forward. Although positive results in the trial process can cause an approval to be priced in before it actually occurs, sometimes the FDA can surprise the market with their decision.
For a look at companies slated to hear back from the FDA on their new drugs, we compiled a list of the companies expecting results by the end of the year.
Do you think these companies’ drugs will be approved? If so, has it already been priced in?
Use this list as a starting point for your own analysis.
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize annual returns for all stocks mentioned
1. Antares Pharma Inc. (AIS): Focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. Market cap of $271.20M. By 12/08, the FDA will make a decision on Anturol Gel for overactive bladder
2. Protalix BioTherapeutics, Inc. (PLX): Focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. Market cap of $520.57M. By 2/01, the FDA will make a decision on Taliglucerase to treat Gaucher disease .
3. Corcept Therapeutics Incorporated (CORT): Engages in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. Market cap of $270.38M. By 2/17, the FDA will make a decision on Corlux for treating Cushing's Syndrome.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.